Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02289326 · ClinicalTrials.gov registry record

Biomarker Monitoring in TP53 Mutation Carriers

A clinical trial, sponsored by Scripps Health.

Completed
Registry status
6
Enrollment target

NCT02289326: Completed study, sponsored by Scripps Health.

NCT02289326 is a clinical trial that has completed, run by Scripps Health. The registered enrollment target is 6 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02289326 has completed, sponsored by Scripps Health.

COMPLETED
Registry status
6 participants
Enrollment target

Study Summary

Purpose This study is an 'N-of-one' observational study focusing on individuals with a hereditary predisposition to cancer due to a genetic mutation in the TP53 gene. An individual with this mutation has a \>90% chance of developing many different forms of cancer in their lifetime. Since germline TP53 gene mutation carriers are highly susceptible to cancer, cancer prevention strategies and early cancer detection strategies are crucial. Unfortunately, the current standard of care for monitoring germline TP53 gene mutation carriers for early signs of cancer is yearly MRI scans and intermittent blood draws. Villani et al. showed that standard monitoring is inadequate and introduced a more sophisticated protocol for early cancer detection. We extended the Villani et al. protocol to include a number of markers for early detection and are currently vetting their utility, in terms of their inherent variability, patient tolerability of frequent interrogation, and ability to show changes that might indicate a need for further examination. In addition to the markers being collected, important covariate information, such as diet, sleep, and activities are being collected (via, e.g., wearable wireless devices) in order to take them into account in assessing the levels of the markers at a single data collection time or over time. One important aspect of the protocol is to identify changes, rather than specific levels, in marker status over time for an individual that might be indicative of tumor formation, essentially exploiting the concept of 'personalized thresholds' discussed by Drescher et al. If any indication of the presence of a cancer, tumorigenic process, or general sign of ill-health is observed, the protocol calls for a discussion of the findings among the research team, followed by a discussion between the clinical lead on the research team and the primary care provider and/or specialists overseeing a participating patient's care, possible validation of the assay(

Trial Details

FieldValue
Enrollment Target 6 participants
Start Date 2014-07
Est. Completion 2016-07
Scripps Health

30 total trials

What the finished NCT02289326 record still lists

NCT02289326 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 6 participants, a relatively small participant target.

The record links to 0 conditions, and to 0 interventions.

NCT02289326 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02289326 about?

NCT02289326 is a clinical study titled "Biomarker Monitoring in TP53 Mutation Carriers". Purpose This study is an 'N-of-one' observational study focusing on individuals with a hereditary predisposition to cancer due to a genetic mutation in the TP53 gene. An individual with this mutation has a \>90% chance of developing many different forms of cancer in their lifetime. Since germline T...

What is the current status of trial NCT02289326?

This trial is currently completed. The enrollment target is 6 participants. The study started on 2014-07. Estimated completion is 2016-07.

Who is sponsoring clinical trial NCT02289326?

This trial is sponsored by Scripps Health, which has 30 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02289326, the US trial registry maintained by the National Library of Medicine. NCT02289326 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.